<DOC>
	<DOC>NCT00239330</DOC>
	<brief_summary>The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.</brief_summary>
	<brief_title>Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male or female subjects, age &gt; 18 years Primary hypercholesterolaemia with CV risk &gt; 20% (as defined in European Guidelines ) and/or type II diabetes and/or a history of CHD or other established atherosclerotic disease. Subjects may be lipidlowering therapy naïve or have been treated for min. 4 weeks with a 'start' dose of any lipidlowering therapy, which was ineffective. Naïve subjects must have completed 12weeks dietary counselling before this visit. Known heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia). Documented secondary hypercholesterolaemia of any cause other than named in inclusion criteria 3. Serious or unstable medical condition Statin contraindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>high blood cholesterol levels</keyword>
</DOC>